3.9.21 Isotretinion Pathway
|Isotretinoin pathway Commissioners have been working with UHS and About Health Ltd to introduce a community based isotretinoin initiation phase one pathway which will commence on 10 September 2021 for male patients over 16 years. |
The phase two pathway will be further developed for females in due course.
The criteria can be found in the attached document.
How to make a referral
• The GP should review the inclusion criteria
• Complete referral form or by letter from the GP containing all the required information on the acne referral proforma (will be available on Ardens/GP Portal)
• Submit referral via e-RS
Treatment will be for a 16 week period. The patient will have full medical history taken and a number of baseline investigations to ensure that they are suitable for the treatment. Throughout the treatment the patient will be monitored for unexpected side effects.
The patient will receive extensive counselling on the risks and benefits of the drug and verbally consent to treatment. The patient will also be given written information regarding the drug, its side effects, risks and benefits. It should also contain information on whom and how they contact a clinician in the event of side effects occurring. Information provided will be BAD patient information leaflet.
Patients should be reviewed 6 weeks after finishing a course of isotretinoin. Response to treatment should be recorded and advice given regarding treatment of relapse ( 60% of patients will require some follow-up treatment for recurrent acne, usually significantly less severe than prior to treatment. 20% of patients will require a second course of isotretinoin at some point however).
Thank you for your support with this.